AT-56

AT-56 is a selective, competitive, and highly bioavailable inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS) with a K_i value of 75 µM.¹ It inhibits the production of PGD₂ by L-PGDS-expressing cells purified from human CSF and recombinant mouse cells with an IC₅₀ value of 95 µM.¹ At concentrations as high as 100 µM in vitro or 30 mg/kg in vivo, AT-56 does not affect the production of PGE₂, PGF_2α, or H-PGDS-catalyzed PGD₂.¹ At 10 mg/kg AT-56, the numbers of total cells, infiltrating eosinophils, and monocytes in bronchoalveolar lavage fluid of L-PGDS transgenic mice were decreased to 23, 6, and 41% of controls, respectively.¹

WARNING This product is not for human or veterinary use.

1. Irikura, D., Aritake, K., Nagata, N., et al. Biochemical, functional, and pharmacological characterization of AT-56, an orally active and selective inhibitor of lipocalin-type prostaglandin D synthase. The Journal of Biological Chemisty 284(12), 7623-7630 (2009).